Zanubrutinib is Well Tolerated and Effective in Acalabrutinib-Intolerant Patients with B-cell Malignancies

被引：0
|
作者：
Shadman, Mazyar [1 ,2 ]
Flinn, Ian W. [3 ]
Levy, Moshe Y. [4 ]
Freeman, Benjamin B. [5 ]
Zhang, Ben [6 ]
Burke, John M. [7 ]
Cultrera, Jennifer L. [8 ]
Yimer, Habte A. [9 ]
Kingsley, Edwin C. [10 ]
Farber, Charles M. [11 ]
D'Olimpio, James [12 ]
Yao, Hui [13 ]
Idoine, Adam [14 ]
An, Qi [13 ]
Sharman, Jeff P. [15 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA USA
[2] Univ Washington, Seattle, WA USA
[3] Tennessee Oncol, OneOncol, Nashville, TN USA
[4] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[5] Summit Med Grp, Florham Pk, NJ USA
[6] Minnesota Oncol Clin, Burnsville, MN USA
[7] US Oncol Res, Rocky Mt Canc Ctr, Aurora, CO USA
[8] Florida Canc Specialists & Res Inst, Leesburg, FL USA
[9] US Oncol Res, Texas Oncol Tyler, Tyler, TX USA
[10] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[11] Morristown Med Ctr, Atlantic Hematol Oncol, Morristown, NJ USA
[12] Clin Res Alliance, Westbury, NY USA
[13] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China
[14] BeiGene USA Inc, San Mateo, CA USA
[15] US Oncol Res, Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-198250
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4632 / 4633
页数：2
相关论文
共 50 条
  • [21] Rate of Atrial Fibrillation in Patients With B-Cell Malignancies Who Undergo Treatment With Zanubrutinib
    Tam, Constantine S.
    Wallis, Nicola
    Zhang, Meng
    Azmi, Soraya
    Zhang, Jun
    Cohen, Aileen
    Sager, Philip T.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S25 - S26
  • [22] Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies
    Ou, Ying C.
    Liu, Lucy
    Tariq, Bilal
    Wang, Kun
    Jindal, Ashutosh
    Tang, Zhiyu
    Gao, Yuying
    Sahasranaman, Srikumar
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (02): : 764 - 772
  • [23] Biomarker Analysis of Zanubrutinib and Tislelizumab Combination Therapy in Patients with Relapsed/Refractory B-Cell Malignancies
    Lyu, Jiaoyan
    Ma, Xiaopeng
    Huang, Ruiqi
    Zhao, Liyun
    Yu, Yiling
    Puig, Oscar
    Liu, Yang
    Hilger, James
    BLOOD, 2022, 140 : 3521 - 3522
  • [24] Bendamustine is an effective and well tolerated therapy in heavily pretreated patients with B-cell chronic lymphocytic leukemia.
    Henze, L
    Aivado, M
    Burger, J
    Kuendgen, A
    Strupp, C
    Schulte, K
    Kronenwett, R
    Finke, J
    Haas, R
    BLOOD, 2002, 100 (11) : 388A - 388A
  • [25] INCIDENT HYPERTENSION AND CLINICAL OUTCOMES AFTER ACALABRUTINIB INITIATION FOR B-CELL MALIGNANCIES
    Chen, Sunnia T.
    Azali, Leylah
    Rosen, Lindsay
    Zhao, Qiuhong
    Wiczer, Tracy
    Palettas, Marilly
    Gambril, John
    Kola-Kehinde, Onaopepo
    Ruz, Patrick
    Rogers, Kerry
    Kittai, Adam
    Grever, Michael
    Awan, Farrukh
    Byrd, John C.
    Bhat, Seema A.
    Addison, Daniel
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1830 - 1830
  • [26] Assessing Hematologist's Knowledge of the Use of Ibrutinib and Acalabrutinib in B-Cell Malignancies
    Willis, Lauren
    Tanzola, Melinda
    Furman, Richard R.
    BLOOD, 2018, 132
  • [27] Mosunetuzumab Retreatment Is Effective and Well-Tolerated in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
    Cheah, Chan Yoon
    Bartlett, Nancy L.
    Assouline, Sarit
    Schuster, Stephen J.
    Kim, Won Seog
    Shadman, Mazyar
    Isufi, Iris
    Yin, Shen
    Doral, Michelle Y.
    Sit, Jason
    Chen, Vivian
    Huang, Huang
    Zhou, Mingzhu
    Wei, Michael C.
    Budde, L. Elizabeth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S455 - S455
  • [28] Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies
    Abbas, Hussein A.
    Wierda, William G.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [29] Population Pharmacokinetics of Bruton Tyrosine Kinase Inhibitor, Acalabrutinib, in Healthy Volunteers and Patients with B-Cell Malignancies
    Edlund, Helena
    Andrew, Marilee
    Jin, Feng
    Patel, Priti
    Masson, Eric
    Slatter, J. Greg
    Aksenov, Sergey
    Al-Huniti, Nidal
    BLOOD, 2017, 130
  • [30] A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies
    Collins, Graham P.
    Clevenger, Tracy N.
    Burke, Kathleen A.
    Yang, Buyue
    MacDonald, Alex
    Cunningham, David
    Fox, Christopher P.
    Goy, Andre
    Gribben, John
    Nowakowski, Grzegorz S.
    Roschewski, Mark
    Vose, Julie M.
    Vallurupalli, Anusha
    Cheung, Jean
    Raymond, Amelia
    Nuttall, Barrett
    Stetson, Dan
    Dougherty, Brian A.
    Schalkwijk, Stein
    Carnevalli, Larissa S.
    Willis, Brandon
    Tao, Lin
    Harrington, Elizabeth A.
    Hamdy, Ahmed
    Izumi, Raquel
    Pease, J. Elizabeth
    Frigault, Melanie M.
    Flinn, Ian
    LEUKEMIA & LYMPHOMA, 2021, 62 (11) : 2625 - 2636
12345